National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Dictionary of Cancer Terms
In English   En español
Page Options
Print This Page
More NCI Dictionaries
NCI Drug Dictionary

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
In English   En español

Kepivance (KEH-puh-vants)

 A form of keratinocyte growth factor (KGF) that is made in the laboratory. KGF stimulates the growth of cells that line the surface of the mouth and intestinal tract. Kepivance is used to prevent and treat oral mucositis (mouth sores) caused by high-dose chemotherapy and radiation therapy in leukemia and lymphoma. It is also being studied in the prevention and treatment of oral mucositis and dysphagia (difficulty swallowing) in other types of cancer. Kepivance is a type of recombinant human keratinocyte growth factor. Also called palifermin.



Previous Definitions:Kassebaum Kennedy Act, kava kava, keloid, kelp, Kemstro
Next Definitions:Keppra, keratan sulfate, keratinocyte growth factor, keratoacanthoma, Ketalar

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov